BioCentury
ARTICLE | Finance

Ebb & Flow

October 18, 2004 7:00 AM UTC

Investors in PharmAthene's $50 million series B round are betting that there's more than the conventional cost-plus 10% in government biodefense contracts.

PharmAthene, which is essentially a biodefense play, has an anthrax therapeutic in preclinical development. ToxBlox, an inhibitor of anthrax toxin, is slated to start Phase I testing next month. ...